Abstract
ErbB4, a member of the epidermal growth factor receptor family, plays a role in normal breast and breast cancer development by regulating mammary epithelial cell proliferation, survival and differentiation. In this study, we show that WWP1, a C2-WW-HECT type E3 ubiquitin ligase, binds, ubiquitinates and destructs ErbB4-CYT1, but much less efficiently for CYT2, isoforms (both JMa and JMb). The protein–protein interaction occurs primarily between the first and third WW domains of WWP1 and the second PY motif of ErbB4. Knockdown of WWP1 by two different small interfering RNAs increases the endogenous ErbB4 protein levels in both MCF7 and T47D breast cancer cell lines. In addition, overexpression of the wild type, but not the catalytic inactive WWP1, dramatically decreases the endogenous ErbB4 protein levels in MCF7. Importantly, we found that WWP1 negatively regulates the heregulin-β1-stimulated ErbB4 activity as measured by the serum response element report assay and the BRCA1 mRNA expression. After a systematic screening of all WWP1 family members by small interfering RNA, we found that AIP4/Itch and HECW1/NEDL1 also negatively regulate the ErbB4 protein expression in T47D. Interestingly, the protein expression levels of both WWP1 and ErbB4 are higher in estrogen receptor-α-positive than in estrogen receptor-α-negative breast cancer cell lines. These data suggest that WWP1 and its family members suppress the ErbB4 expression and function in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y et al. (2005). WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764–6772.
Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ . (2005). Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163–2168.
Chen C, Matesic LE . (2007). The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 26: 587–604.
Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X et al. (2005). Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280: 41553–41561.
Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W et al. (2007a). Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26: 2386–2394.
Chen C, Zhou Z, Liu R, Li Y, Azmi PB, Seth AK . (2008). The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. Oncogene 27: 6845–6855.
Chen C, Zhou Z, Ross JS, Zhou W, Dong JT . (2007b). The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 121: 2834–2841.
Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, Boguniewicz A et al. (2009). Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1(IGF-1R) in breast carcinoma. Int J Cancer 124: 2829–2836.
Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K et al. (2009). The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol 29: 892–906.
Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS et al. (2007). The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol 21: 1861–1876.
Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M et al. (2006). Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 25: 5664–5672.
Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ, Glimcher LH . (2006). Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science 312: 1223–1227.
Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P et al. (2005). Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65: 1384–1393.
Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ et al. (2000). c-erbB-4 protein expression in human breast cancer. Br J Cancer 82: 1163–1170.
Komuro A, Nagai M, Navin NE, Sudol M . (2003). WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278: 33334–33341.
Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E et al. (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 99: 1775–1785.
Li Y, Ozaki T, Kikuchi H, Yamamoto H, Ohira M, Nakagawara A . (2008a). A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. Oncogene 27: 3700–3709.
Li Y, Zhou Z, Chen C . (2008b). WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15: 1941–1951.
Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L et al. (2003). Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130: 5257–5268.
Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J et al. (2006). Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 17: 67–79.
Miyazaki K, Fujita T, Ozaki T, Kato C, Kurose Y, Sakamoto M et al. (2004). NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem 279: 11327–11335.
Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE et al. (2006a). Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol 26: 6412–6424.
Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp III HS . (2008). Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol Endocrinol 22: 2307–2321.
Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM et al. (2006b). The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 17: 4118–4129.
Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI et al. (2006). The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66: 6412–6420.
Nguyen Huu NS, Ryder WD, Zeps N, Flasza M, Chiu M, Hanby AM et al. (2008). Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. J Pathol 216: 93–102.
Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L et al. (2004). Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294: 469–479.
Omerovic J, Santangelo L, Puggioni EM, Marrocco J, Dall’Armi C, Palumbo C et al. (2007). The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 21: 2849–2862.
Pitfield SE, Bryant I, Penington DJ, Park G, Riese II DJ . (2006). Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res 16: 179–193.
Seo SR, Lallemand F, Ferrand N, Pessah M, L’Hoste S, Camonis J et al. (2004). The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 23: 3780–3792.
Strunk KE, Husted C, Miraglia LC, Sandahl M, Rearick WA, Hunter DM et al. (2007). HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res 67: 6582–6590.
Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K . (2008). Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13: 259–268.
Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM . (2001). Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 439: 62–69.
Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME . (1999). Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 59: 5315–5322.
Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP . (2003). Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA 100: 8281–8286.
Vidal GA, Clark DE, Marrero L, Jones FE . (2007). A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 26: 462–466.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM . (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290–297.
Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L et al. (2006). Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66: 7991–7998.
Acknowledgements
This work was supported in part by grants from the Department of Defense BCRP concept award (W81XWH-08-1-0557) and PCRP IDEA award (W81XWH-07-1-0191), a Research Scholar Award from the American Cancer Society and a Grant (BCTR0503705, Chen, C) from Komen for the Cure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, Y., Zhou, Z., Alimandi, M. et al. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 28, 2948–2958 (2009). https://doi.org/10.1038/onc.2009.162
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.162
Keywords
This article is cited by
-
The role of NEDD4 related HECT-type E3 ubiquitin ligases in defective autophagy in cancer cells: molecular mechanisms and therapeutic perspectives
Molecular Medicine (2023)
-
WWP1 E3 ligase at the crossroads of health and disease
Cell Death & Disease (2023)
-
HECW1 induces NCOA4-regulated ferroptosis in glioma through the ubiquitination and degradation of ZNF350
Cell Death & Disease (2023)
-
WWP1 upregulation predicts poor prognosis and promotes tumor progression by regulating ubiquitination of NDFIP1 in intrahepatic cholangiocarcinoma
Cell Death Discovery (2022)
-
Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma
BMC Cancer (2021)